ClinicalTrials.gg
CompletedNCT02087306Updated Aug 13, 2021Results posted

Study to Assess the Safety and Efficacy of Brincidofovir in Treatment of Early Versus Late Adenovirus Infection

A Phase 3 interventional study of Brincidofovir in Adenovirus Infection, sponsored by Chimerix. Completed at 33 sites in United States. Open to participants aged 2 Months and older. Per ClinicalTrials.gov, last updated 2021-08-13.

Sponsored by Chimerix (part of Jazz Pharmaceuticals) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
201
Allocation
Not applicable
Ages
2 Months and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 78 studies in Adenoviridae Infections with a site in United States — 17 open to participants now, 21 under way, 2 of them phase 3. Adenoviridae Infections · United States.

Enrollment
10th of 68
201 · median 27
Started
2014
with 6 others
Phase 3
6 of 78
2 open now
Registered
37th of 78
by date
Lead sponsor
6 of 78
Chimerix

Among the 78 studies in Adenoviridae Infections with a site in United States, this one is the 10th largest by enrollment of the 68 interventional ones that give a count, is one of 7 that started in 2014, is one of 6 in phase 3, and was the 37th registered.

Adenoviridae Infections

136 studies on the registry are indexed under Adenoviridae Infections; 34 are open to participants now.

Browse Adenoviridae Infections studies →

Open to participants now

17 of the 78 studies in Adenoviridae Infections with a site in United States are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 25 Adenoviridae Infections studies recruiting now, 9 (36%) set no upper age limit and 12 (48%) stop at 75 or younger; 17 take children under 18; 4 take healthy volunteers.

This study: 2 Months and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in Adenoviridae Infections with a site in United States, or all of them as a file.
02

Study summary

This was a Phase 3 open-label, non-randomized, multicenter study of oral brincidofovir (BCV) administered twice weekly for the treatment of adenovirus (AdV) infection detected during asymptomatic AdV viremia or during symptomatic AdV infection.

Read the detailed description

This was a Phase 3 open-label, non-randomized, multicenter study of the safety, tolerability, and efficacy of oral brincidofovir (BCV) when administered twice weekly for the treatment of disseminated adenovirus (AdV) disease and for the treatment of AdV infection when treatment was initiated in subjects who were at risk of progression to disseminated disease (i.e., during the asymptomatic or localized phases of infection).

03

Conditions studied

  • Adenovirus Infection

Keywords

  • Adenovirus Infection
04

Who can participate

Ages eligible
2 Months and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria Subjects were required to meet all of the following criteria, as applicable, to be eligible to participate in this study.

  1. Were male or female, aged 2 months or older.
  2. Had either of the following:

    • Disseminated adenovirus (AdV) disease; or
    • An underlying state and were at risk of progression to disseminated AdV disease.

    [Note: Subjects with symptomatic AdV infection (i.e., localized or disseminated AdV disease) could have been screening immediately, with brincidofovir (BCV) therapy initiated after receipt of the screening virology results from the designated central virology laboratory confirming study eligibility. Subjects with asymptomatic AdV infection (i.e., had no symptoms of AdV disease) could have been consented and screened only if they had at least 1 positive or detectable AdV DNA (quantitative [q]) polymerase chain reaction (PCR) test (in any blood fluid or compartment) from the local virology laboratory, with treatment initiated only after confirmation of AdV positivity by 2 separate measurements at the designated central virology laboratory. Where the results from 2 AdV DNA (q)PCR measurements in plasma or non-plasma body fluid or compartment were needed to show that a subject was at risk of progression to disseminated AdV disease, the second measurement had to be resulted prior to the initiation of BCV therapy.]

  3. Were able to ingest and absorb oral medication (in the judgement of the investigator and based on lack of significant gastrointestinal [GI] events/medical history).
  4. If male of , were willing to use an acceptable method(s) during sexual intercourse with a female partner of reproductive potential throughout the duration of this participation in the study and for at least 6 months after his last dose of BCV.
  5. If female of reproductive potential, i.e., not premenarche, , surgically sterile, or had documented ovarian failure, were willing to use 2 acceptable contraceptive methods, 1 of which must have been a barrier method, during sexual intercourse with a nonsterile male partner, throughout the duration of her participation in the study and for at least 6 months after her last dose of BCV.
  6. Were willing and able to understand and provide written to participate in the study. [Note: If the subject was under 18 years of age or was otherwise unable to legally give his or her informed consent to participate in the study, then written informed consent to participate had to be obtained from the parent(s) or legal guardian(s) of the subject or other legal personal representative(s), as applicable. In addition, in the case of minor subjects, the written assent of the subject to participate in the study was obtained where required by applicable institutional policy on the consenting of minor study participants.]
  7. The subject and his or her caregivers (as applicable) were willing and able to participate in all required study activities for the entire duration of the study (i.e., through completion of Week 36).

Exclusion Criteria

Subjects who met any of the following criteria (as applicable) were not eligible to participate in this study:

  1. If a female of reproductive potential, the subject was pregnant, planning to become pregnant during the study or within 6 months after their anticipated last BCV dose, or was nursing a child.
  2. Had (not including renal dysfunction or eye disorder) to cidofovir (CDV) or to BCV or its formulation .
  3. Had received treatment with another drug within 14 days prior to Day 1 unless prior approval was received from the Chimerix medical monitor (or designee).
  4. Were participating in another interventional clinical trial unless prior approval was received from the Chimerix medical monitor (or designee).
  5. Had previously received an anti-AdV vaccine or a cell-based anti-AdV therapy.
  6. Were receiving intravenous (IV) CDV, leflunomide, vidarabine, systemic ribavirin, or another investigational anti-AdV drug at Day 1. [Note: Subjects who were receiving treatment with IV CDV prior to enrollment had to discontinue IV CDV and wait until a minimum of 48 hours had elapsed from last IV CDV administration before initiating BCV therapy. All other drugs had to be discontinued prior to Day 1.]
  7. Were receiving digoxin or ketoconazole (other than topical formulations) at Day 1 or were anticipated to need treatment with either drug during the treatment phase of the study.
  8. Were infected with , virus (HBV), and/or virus (HCV), had evidence of active viral replication within 6 months prior to screening, as demonstrated by detectable HIV or HCV RNA, or had detectable HBV DNA in blood, plasma or serum.
  9. Had end-stage renal disease, i.e., an estimated \<15 mL/min, unless receiving renal replacement therapy.
  10. Had a serum or aspartate aminotransferase concentration >5 x the (ULN), or a serum total concentration >2 x the ULN and a serum direct (conjugated) bilirubin concentration >1.5 x the ULN, as reported by the central safety laboratory, unless, in the judgment of the investigator, the abnormality(ies) was/were related to the subject's AdV infection/disease.
  11. Had ongoing Grade 3 or higher diarrhea, unless, in the judgment of the investigator, the diarrhea was related to the subject's underlying AdV infection/disease.
  12. Had Stage 3 or higher (GVHD) of the intestine (GI-GVHD or any other GI disease that would have, in the judgment of the investigator, precluded the subject from taking or absorbing oral medication (e.g., clinically active Crohn's disease, ischemic colitis, moderate or severe ulcerative colitis, small bowel resection, ileus, or any condition expected to require abdominal surgery during the course of study participation).
  13. Had any other condition, including abnormal laboratory values, that would have, in the judgment of the investigator, put the subject at increased risk by participating in the study, or would have interfered with the conduct or planned analyses of the study.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
201 participants (actual)

Study arms

  • Experimental
    Brincidofovir

    Subjects who weighed \<50 kg received 2 mg/kg (not to exceed 100 mg) BCV twice weekly administered orally as the appropriate volume of 10-mg/mL liquid suspension. Subjects who weighed ≥50 kg received 100 mg BCV twice weekly administered orally as one 100 mg tablet (or the appropriate volume of 10-mg/mL liquid suspension if unable to swallow solid medicine).

    Drug: Brincidofovir

Interventions

  • BCV administered twice weekly, dose depending on weight.

    Also known as: BCV, CMX001

06

What researchers measure

Primary outcomes

  1. Number of Participants With All-Cause Mortality

    The primary efficacy endpoint was the evaluation of the effect of brincidofovir (BCV) on all-cause mortality when used for the treatment of disseminated adenovirus (AdV) disease in all hematopoietic cell transplant (HCT) recipients. The primary endpoint associated with this objective was all-cause mortality through Day 60.

    Time frame: 60 days

Secondary outcomes

  1. Number of Participants With Reduction in Adenovirus Viremia

    A secondary endpoint was the evaluation of virologic response (plasma adenovirus \[AdV\] DNA viremia) to brincidofovir treatment. Blood (plasma) was collected at screening, before dosing on Day 1 (to establish baseline), and at each subsequent assessment during the treatment and post-treatment phases for the analysis of AdV DNA viremia. All samples collected for analysis of AdV were analyzed by the designated central virology laboratory using proprietary real-time quantitative polymerase chain reaction (qPCR) assays. AdV in plasma were analyzed using the 7500 AdV qPCR Test, where the standardized assay plasma ranged from 190 copies/mL to 1 X 10\^10 copies/mL. A "positive or detectable" result referred to the measurement of AdV DNA at concentrations ≥190 copies/mL, a result below the lower limit of detection (LLOQ) (i.e., not detected) was imputed as 1 copy/mL, and a result below the lower limit of quantitation but detected will be imputed at 1 unit less than LLOQ (e.g., 189 copies/mL).

    Time frame: Assessed 13 weeks (through 7 days post-last BCV dose); during treatment up to 12 weeks reported

  2. Mean Minimum On-treatment Value log10 Copies/mL Change From Baseline

    A secondary endpoint was the evaluation of virologic response (plasma adenovirus \[AdV\] DNA viremia) to brincidofovir treatment. Blood (plasma) was collected at screening, before dosing on Day 1 (to establish baseline), and at each subsequent assessment during the treatment and post-treatment phases for the analysis of AdV DNA viremia. All samples collected for analysis of AdV were analyzed by the designated central virology laboratory using proprietary real-time quantitative polymerase chain reaction (qPCR) assays. AdV in plasma were analyzed using the 7500 AdV qPCR Test, where the standardized assay plasma ranged from 190 copies/mL to 1 X 10\^10 copies/mL. A "positive or detectable" result referred to the measurement of AdV DNA at concentrations ≥190 copies/mL, a result below the lower limit of detection (LLOQ) (i.e., not detected) was imputed as 1 copy/mL, and a result below the lower limit of quantitation but detected will be imputed at 1 unit less than LLOQ (e.g., 189 copies/mL).

    Time frame: Baseline to 12 weeks

07

Results

Posted Aug 13, 2021

Participant flow

Participant flow — Overall Study
MilestoneCohort ACohort BCohort C
Started659343
Completed292916
Not completed366427

Outcome measures

PrimaryNumber of Participants With All-Cause Mortality

The primary efficacy endpoint was the evaluation of the effect of brincidofovir (BCV) on all-cause mortality when used for the treatment of disseminated adenovirus (AdV) disease in all hematopoietic cell transplant (HCT) recipients. The primary endpoint associated with this objective was all-cause mortality through Day 60.

Time frame:
60 days
Reported as:
Count of participants · Participants
Number of Participants With All-Cause Mortality
ParticipantsCohort ACohort BCohort C
Number of Participants With All-Cause Mortality9278
SecondaryNumber of Participants With Reduction in Adenovirus Viremia

A secondary endpoint was the evaluation of virologic response (plasma adenovirus \[AdV\] DNA viremia) to brincidofovir treatment. Blood (plasma) was collected at screening, before dosing on Day 1 (to establish baseline), and at each subsequent assessment during the treatment and post-treatment phases for the analysis of AdV DNA viremia. All samples collected for analysis of AdV were analyzed by the designated central virology laboratory using proprietary real-time quantitative polymerase chain reaction (qPCR) assays. AdV in plasma were analyzed using the 7500 AdV qPCR Test, where the standardized assay plasma ranged from 190 copies/mL to 1 X 10\^10 copies/mL. A "positive or detectable" result referred to the measurement of AdV DNA at concentrations ≥190 copies/mL, a result below the lower limit of detection (LLOQ) (i.e., not detected) was imputed as 1 copy/mL, and a result below the lower limit of quantitation but detected will be imputed at 1 unit less than LLOQ (e.g., 189 copies/mL).

Time frame:
Assessed 13 weeks (through 7 days post-last BCV dose); during treatment up to 12 weeks reported
Reported as:
Count of participants · Participants
Number of Participants With Reduction in Adenovirus Viremia
ParticipantsCohort ACohort BCohort C
Undetectable AdV viremia at any time on-treatment305217
Undetectable AdV viremia at last on-treatment value254116
SecondaryMean Minimum On-treatment Value log10 Copies/mL Change From Baseline

A secondary endpoint was the evaluation of virologic response (plasma adenovirus \[AdV\] DNA viremia) to brincidofovir treatment. Blood (plasma) was collected at screening, before dosing on Day 1 (to establish baseline), and at each subsequent assessment during the treatment and post-treatment phases for the analysis of AdV DNA viremia. All samples collected for analysis of AdV were analyzed by the designated central virology laboratory using proprietary real-time quantitative polymerase chain reaction (qPCR) assays. AdV in plasma were analyzed using the 7500 AdV qPCR Test, where the standardized assay plasma ranged from 190 copies/mL to 1 X 10\^10 copies/mL. A "positive or detectable" result referred to the measurement of AdV DNA at concentrations ≥190 copies/mL, a result below the lower limit of detection (LLOQ) (i.e., not detected) was imputed as 1 copy/mL, and a result below the lower limit of quantitation but detected will be imputed at 1 unit less than LLOQ (e.g., 189 copies/mL).

Time frame:
Baseline to 12 weeks
Reported as:
Mean · log10 copies/mL
Mean Minimum On-treatment Value log10 Copies/mL Change From Baseline
log10 copies/mLCohort ACohort BCohort C
Minimum on-treatment value log10 copies/mL change from baseline-2.67 ± 1.559-3.27 ± 2.163-3.11 ± 2.127
Last on-treatment value log10 copies/mL change from baseline-2.06 ± 1.898-2.61 ± 2.338-2.87 ± 2.291

Adverse events

Collected over Adverse events that started on or after the first dose of BCV up to 7 days after the last dose of BCV (through 13 weeks) are reported.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pediatric—93/130 (71.5%)127/130 (97.7%)
Adult—58/71 (81.7%)71/71 (100%)
Most frequent serious events
Showing 10 of 186
Most frequent serious events
EventPediatricAdult
Septic shockInfections and infestations8/13023/71
Acute graft versus host diseaseImmune system disorders25/13014/71
DiarrhoeaGastrointestinal disorders12/1309/71
PyrexiaGeneral disorders15/1304/71
Respiratory failureRespiratory, thoracic and mediastinal disorders14/1305/71
Multi-organ failureGeneral disorders12/1305/71
Acute kidney injuryRenal and urinary disorders12/1304/71
VomitingGastrointestinal disorders4/1306/71
Adenovirus infectionInfections and infestations3/1305/71
NauseaGastrointestinal disorders0/1305/71
Most frequent other events
Showing 10 of 74
Most frequent other events
EventPediatricAdult
DiarrhoeaGastrointestinal disorders58/13026/71
PyrexiaGeneral disorders48/13016/71
Acute graft versus host diseaseImmune system disorders43/13023/71
Abdominal painGastrointestinal disorders20/13023/71
VomitingGastrointestinal disorders27/13020/71
NauseaGastrointestinal disorders10/13018/71
FatigueGeneral disorders5/13014/71
HypotensionVascular disorders17/13014/71
Alanine aminotransferase increasedInvestigations25/1308/71
Aspartate aminotransferase increasedInvestigations23/1308/71

Baseline characteristics

Age, Continuous
Age, Continuous(years)Cohort ACohort BCohort CTotal
Mean19 ± 17.420 ± 23.117 ± 21.919 ± 21.1
Sex: Female, Male
Sex: Female, Male(Participants)Cohort ACohort BCohort CTotal
Female26301672
Male396327129
08

Study locations

33 sites
  • Phoenix Children's Hospital
    Phoenix, Arizona 85016, United States
  • Children's Hospital Los Angeles
    Los Angeles, California 90027, United States
  • Stanford Children's Hospital
    Palo Alto, California 94305, United States
  • Stanford University
    Stanford, California 94305, United States
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • Children's National Health System
    Washington, District of Columbia 20010, United States
  • Children's Healthcare of Atlanta, Aflac Cancer and Blood Center
    Atlanta, Georgia 30322, United States
  • Ann & Robert H. Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Children's Hospital
    New Orleans, Louisiana 70118, United States
  • Johns Hopkins University
    Baltimore, Maryland 21231, United States
  • Brigham and Woman's Hospital
    Boston, Massachusetts 02115, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Children's Mercy Hospital
    Kansas City, Missouri 64108, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • University of Nebraska
    Omaha, Nebraska 68198, United States
  • Montifore Medical Center
    Bronx, New York 10467, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Weill Cornell Medical College/ New York Presbyterian Hospital
    New York, New York 10065, United States
  • Levine Children's Hospital
    Charlotte, North Carolina 28203, United States
  • Duke University Medical Center
    Durham, North Carolina 27712, United States
  • Cincinnati Children's Hospital
    Cincinnati, Ohio 45229, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Children's Hospital of Pittsburgh
    Pittsburgh, Pennsylvania 15224, United States
  • St. Jude Children's Hospital
    Memphis, Tennessee 38105, United States
  • Cook Children's Medical Center
    Fort Worth, Texas 76104, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Intermountain Healthcare Research
    Salt Lake City, Utah 84103, United States
  • University of Utah Huntsman Cancer Institute
    Salt Lake City, Utah 84112, United States
  • Fred Hutchingson Cancer Center
    Seattle, Washington 19024, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2014 to primary completion in Jun 2016, 27 months.

Results were first posted in Aug 2021, 5 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2014
First posted
Mar 14, 2014
StartActual
Mar 2014
Primary completionActual
Jun 2016
CompletionActual
Aug 2016
Results first posted
Aug 13, 2021
Last update
Aug 13, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02087306
Lead sponsor
Chimerix
Responsible party
Sponsor
First posted
Mar 14, 2014
Start date
Mar 2014
Primary completion
Jun 2016
Completion
Aug 2016
Results posted
Aug 13, 2021
Last update
Aug 13, 2021

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brincidofovir

Start the discussion